Related references
Note: Only part of the references are listed.Critical role of interleukin (IL)-17 in inflammatory and immune disorders: An updated review of the evidence focusing in controversies
Jose Maria G. Ruiz de Morales et al.
AUTOIMMUNITY REVIEWS (2020)
Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study
Nanshan Chen et al.
LANCET (2020)
A new coronavirus associated with human respiratory disease in China
Fan Wu et al.
NATURE (2020)
The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China
Wen Zhang et al.
CLINICAL IMMUNOLOGY (2020)
Pathological findings of COVID-19 associated with acute respiratory distress syndrome
Zhe Xu et al.
LANCET RESPIRATORY MEDICINE (2020)
Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality
Chi Zhang et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2020)
Tocilizumab treatment in COVID-19: A single center experience
Pan Luo et al.
JOURNAL OF MEDICAL VIROLOGY (2020)
TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib
Dandan Wu et al.
JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION (2020)
Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed
Marc Feldmann et al.
LANCET (2020)
COVID-19: consider cytokine storm syndromes and immunosuppression
Puja Mehta et al.
LANCET (2020)
Elevated plasma levels of selective cytokines in COVID-19 patients reflect viral load and lung injury
Yingxia Liu et al.
NATIONAL SCIENCE REVIEW (2020)
Likelihood of survival of coronavirus disease 2019 Comment
Shigui Ruan
LANCET INFECTIOUS DISEASES (2020)
Secukinumab Demonstrates Significantly Lower Immunogenicity Potential Compared to Ixekizumab
Sebastian Spindeldreher et al.
DERMATOLOGY AND THERAPY (2018)
Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis
K. Reich et al.
BRITISH JOURNAL OF DERMATOLOGY (2017)
Psoriasis pathogenesis and the development of novel targeted immune therapies
Jason E. Hawkes et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2017)
T-cell immunity of SARS-CoV: Implications for vaccine development against MERS-CoV
William J. Liu et al.
ANTIVIRAL RESEARCH (2017)
Psoriasis
Jacqueline E. Greb et al.
NATURE REVIEWS DISEASE PRIMERS (2016)
IL-17 response mediates acute lung injury induced by the 2009 Pandemic Influenza A (H1N1) Virus
Chenggang Li et al.
CELL RESEARCH (2012)
IL-17 Boosts Proinflammatory Outcome of Antiviral Response in Human Cells
Grigory Ryzhakov et al.
JOURNAL OF IMMUNOLOGY (2011)
Critical Role of IL-17RA in Immunopathology of Influenza Infection
Christopher R. Crowe et al.
JOURNAL OF IMMUNOLOGY (2009)